Laurence Miller, MD
Internal Medicine · Ardsley, NYNPI 1407800303
Payments from drug & device makers
Across 318 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Merz North America, Inc.$2K
- GSK$1K
- Boehringer Ingelheim$477
- Novo Nordisk$395
- Sanofi$388
- plus $4K from 27 others
What the payments were for
- Travel & lodging$1,10610%
- Food & beverage$9,50589%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $2,451 |
| Merz North America, Inc. | 22 | $1,996 |
| GSK | 52 | $1,151 |
| Boehringer Ingelheim | 8 | $477 |
| Novo Nordisk | 23 | $395 |
| Sanofi | 20 | $388 |
| Exact Sciences | 11 | $380 |
| Inari Medical, Inc. | 3 | $346 |
| Pfizer | 16 | $310 |
| Inspire Medical Systems, Inc. | 8 | $273 |
| Lilly USA, LLC | 11 | $253 |
| Amgen | 10 | $234 |
| Regeneron Healthcare Solutions, Inc. | 12 | $233 |
| Actelion Pharmaceuticals US, Inc. | 4 | $228 |
| Galderma Laboratories, L.p. | 10 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $185 |
| Grifols USA, LLC | 2 | $184 |
| Mylan Specialty L.p. | 8 | $155 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $121 |
| Insmed, Inc. | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Viatris Specialty LLC | 3 | $74 |
| Novartis | 3 | $70 |
| AbbVie(2 entities) | 3 | $59 |
| Electromed, Inc. | 4 | $54 |
| Baxter Healthcare | 2 | $50 |
| Merck | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $22 |
| Philips North America LLC | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$375
- FASENRA$371
- FLOWTRIEVER CATHETER, S$331
- CT THROMBECTOMY SYSTEM KIT$331
- AIRSUPRA$250
- Inspire$162
- Prolastin-C Liquid$160
- UPTRAVI$140
- OPSUMIT$140
- TEZSPIRE$135
- Cologuard Collection Kit$125
- OFEV$123
- AREXVY$120
- Arikayce$117
- XEOMIN$115
- ASCLERA$115
How this compares
$10,690 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $72,725 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $51,134 |
| JardianceEmpagliflozin | 31 | $51,071 |
| JanuviaSitagliptin Phosphate | 40 | $50,091 |
| EliquisApixaban | 34 | $34,853 |
| MounjaroTirzepatide | 13 | $14,710 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,894 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $9,414 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $6,333 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $5,317 |
| VascepaIcosapent Ethyl | 12 | $3,845 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,522 |
| Atorvastatin Calcium | 283 | $2,606 |
| Rosuvastatin Calcium | 223 | $2,538 |
| Ezetimibe | 68 | $2,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $395 | $72,72577 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,151 | $67,362118 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $477 | $60,48543 claims |
| MerckJanuvia | $24 | $50,09140 claims |
| PfizerEliquis | $310 | $34,85334 claims |
| Lilly USA, LLCMounjaro | $253 | $14,71013 claims |
| AbbVieSynthroid | $59 | $1,59125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Ardsley
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.